AJTMH ASTMH Job Mart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am. J. Trop. Med. Hyg., 71(2 suppl), 2004, pp. 239-247
Copyright © 2004 by The American Society of Tropical Medicine and Hygiene

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (51)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by BALLOU, W. R.
Right arrow Articles by COHEN, J. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by BALLOU, W. R.
Right arrow Articles by COHEN, J. D.
Right arrowPubmed/NCBI databases
Medline Plus Health Information
*Malaria

UPDATE ON THE CLINICAL DEVELOPMENT OF CANDIDATE MALARIA VACCINES

W. RIPLEY BALLOU, MYRIAM AREVALO-HERRERA, DANIEL CARUCCI, THOMAS L. RICHIE, GIAMPIETRO CORRADIN, CARTER DIGGS, PIERRE DRUILHE, BIRGITTE K. GIERSING, ALLAN SAUL, D. GRAY HEPPNER, KENT E. KESTER, DAVID E. LANAR, JEFF LYON, ADRIAN V. S. HILL, WEIQING PAN, AND JOE D. COHEN
Clinical Research and Development, and Research and Development, GlaxoSmithKline Biologicals, Rixensart, Belgium; Malaria Vaccine and Drug Testing Center, Cali, Columbia; Malaria Program, Naval Medical Research Center, Silver Spring, Maryland; University of Lausanne, Lausanne, Switzerland; Malaria Vaccine Development Program, U.S. Agency for International Development, Washington, District of Columbia; Institut Pasteur, Paris, France; Malaria Vaccine Development Unit, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland; Departments of Immunology and Clinical Trials, Walter Reed Army Institute of Research, Silver Spring, Maryland; Centre for Clinical Vaccinology and Tropical Medicine, Oxford University, Oxford, United Kingdom; Second Military Medical University, Shanghai, People’s Republic of China

The recent availability of significantly increased levels of funding for unmet medical needs in the developing world, made available by newly created public-private-partnerships, has proven to be a powerful driver for stimulating clinical development of candidate vaccines for malaria. This new way forward promises to greatly increase the likelihood of bringing a safe and effective vaccine to licensure. The investigators bring together important published and unpublished information that illuminates the status of malaria vaccine development. They focus their comments on those candidate vaccines that are currently in or expected to enter clinical trials in the next 12 months.

Received August 21, 2003. Accepted for publication December 1, 2003.

Acknowledgments: We thank Dr. B. Fenton Hall (National Institute of Allergy and Infectious Diseases, NIH) for providing information concerning the Apovia trial. This report contains published and unpublished data on the current status of malaria vaccines and was presented in part at the Third Multilateral Initiative for Malaria in Arusha, Tanzania, November 2002.

Disclosure: W. Ripley Ballou is an employee and stockholder of GlaxoSmithKline Biologicals.

Authors’ addresses: W. Ripley Ballou, Clinical Research and Development, Emerging Diseases, GlaxoSmithKline Biologicals, 89 Rue de L’Institut, Rixensart, Belgium, Telephone: 32-2-656-6659, Fax: 32-2-656-8133, E-mail: Ripley.Ballou{at}gskbio.com. Myriam Arevalo-Herrera, Malaria Vaccine and Drug Testing Center, Cali, Columbia. Daniel Carucci and Thomas L. Richie, Malaria Program, Naval Medical Research Center, 503 Robert Grant Avenue, Silver Spring, MD 20910. Giampietro Corradin, University of Lausanne, Lausanne CH-1015, Switzerland. Carter Diggs, Malaria Vaccine Development Program, U.S. Agency for International Development, Washington, DC 20523-1000. Pierre Druilhe, Unité de Parasitologie Biomédicale, Institut Pasteur, 28 Rue du Dr Roux, 75015, Paris, France. Birgitte K. Giersing and Allan Saul, Malaria Vaccine Development Unit, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892. D. Gray Heppner, Kent E. Kester, David E. Lanar, and Jeff Lyon, Departments of Immunology and Clinical Trials, Walter Reed Army Institute of Research, 503 Robert Grant Avenue, Silver Spring, MD 20910. Adrian V. S. Hill, Centre for Clinical Vaccinology and Tropical Medicine, Oxford University, Oxford OX3 7LJ, United Kingdom. Weiqing Pan, Second Military Medical University, Shanghai, People’s Republic of China. Joe D. Cohen, GlaxoSmithKline Biologicals, 89 Rue de L’Institut, Rixensart, Belgium.




This article has been cited by other articles:


Home page
 Am J Trop Med HygHome page
E. S. HIGGS and B. SINA
PLASMODIUM VIVAX VACCINE RESEARCH: STEPS IN THE RIGHT DIRECTION
Am J Trop Med Hyg, November 1, 2005; 73(5_suppl): 1 - 2.
[Full Text] [PDF]

Home page
 Am J Trop Med HygHome page
A. JORDAN-VILLEGAS, J. C. ZAPATA, A. B. PERDOMO, G. E. QUINTERO, Y. SOLARTE, M. AREVALO-HERRERA, and S. HERRERA
AOTUS LEMURINUS GRISEIMEMBRA MONKEYS: A SUITABLE MODEL FOR PLASMODIUM VIVAX SPOROZOITE INFECTION
Am J Trop Med Hyg, November 1, 2005; 73(5_suppl): 10 - 15.
[Abstract] [Full Text] [PDF]

Home page
 Infect. Immun.Home page
S. Dutta, D. C. Kaushal, L. A. Ware, S. K. Puri, N. A. Kaushal, A. Narula, D. S. Upadhyaya, and D. E. Lanar
Merozoite Surface Protein 1 of Plasmodium vivax Induces a Protective Response against Plasmodium cynomolgi Challenge in Rhesus Monkeys
Infect. Immun., September 1, 2005; 73(9): 5936 - 5944.
[Abstract] [Full Text] [PDF]

Home page
 Am J Trop Med HygHome page
T. M. TRAN, J. OLIVEIRA-FERREIRA, A. MORENO, F. SANTOS, S. S. YAZDANI, C. E. CHITNIS, J. D. ALTMAN, E. V-S. MEYER, J. W. BARNWELL, and M. R. GALINSKI
COMPARISON OF IgG REACTIVITIES TO PLASMODIUM VIVAX MEROZOITE INVASION ANTIGENS IN A BRAZILIAN AMAZON POPULATION
Am J Trop Med Hyg, August 1, 2005; 73(2): 244 - 255.
[Abstract] [Full Text] [PDF]

Home page
 Postgrad. Med. J.Home page
D L Gardiner, J S McCarthy, and K R Trenholme
Malaria in the post-genomics era: light at the end of the tunnel or just another train?
Postgrad. Med. J., August 1, 2005; 81(958): 505 - 509.
[Abstract] [Full Text] [PDF]

Home page
 Infect. Immun.Home page
B. Giersing, K. Miura, R. Shimp, J. Wang, H. Zhou, A. Orcutt, A. Stowers, A. Saul, L. H. Miller, C. Long, et al.
Posttranslational Modification of Recombinant Plasmodium falciparum Apical Membrane Antigen 1: Impact on Functional Immune Responses to a Malaria Vaccine Candidate
Infect. Immun., July 1, 2005; 73(7): 3963 - 3970.
[Abstract] [Full Text] [PDF]

Home page
 Health Aff (Millwood)Home page
S. Landry and C. Heilman
Future Directions In Vaccines: The Payoffs Of Basic Research
Health Aff., May 1, 2005; 24(3): 758 - 769.
[Abstract] [Full Text] [PDF]

Home page
 Am J Trop Med HygHome page
G. K. Isbister, J. White, B. J. Currie, S. P. Bush, R. S. Vetter, and D. A. Warrell
SPIDER BITES: ADDRESSING MYTHOLOGY AND POOR EVIDENCE
Am J Trop Med Hyg, April 1, 2005; 72(4): 361 - 364.
[Full Text] [PDF]

Home page
 Am J Trop Med HygHome page
J. H. Diaz
MOST NECROTIC ULCERS ARE NOT SPIDER BITES
Am J Trop Med Hyg, April 1, 2005; 72(4): 364 - 367.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by the American Society of Tropical Medicine and Hygiene.